Background & Aims: Ursodeoxycholic acid (UDCA) is used for the treatment of cholestatic
liver diseases including primary biliary cirrhosis (PBC) for which it has a positive effect on …

BACKGROUND/AIMS: Ursodeoxycholic acid (UDCA) has been shown to improve serum
liver tests in primary sclerosing cholangitis (PSC), but controlled trials have shown …

OBJECTIVES: To assess the tolerability and efficacy of high-dose (25–30 mg/kg per day)
ursodeoxycholic acid (UDCA) in patients with primary sclerosing cholangitis (PSC) …

Previous controlled trials are inconclusive regarding the efficacy of ursodeoxycholic acid
(UDCA) for treating primary sclerosing cholangitis (PSC). One hundred fifty adult patients …

Background/Aims: Ursodeoxycholic acid has been reported to be of potential benefit for
primary sclerosing cholangitis but little is known about the long-term biochemical …

The effects of ursodeoxycholic acid (UDCA, 750–1250 mg/day) were evaluated
prospectively in 15 patients with primary sclerosing cholangitis (PSC). Five patients had …

Primary sclerosing cholangitis is a cholestatic disease of the liver characterized by
progressive fibrotic inflammation and obliteration of the extra-and/or intrahepatic bile ducts …

We investigated the effects of once-daily oral administration of 10 mg/kg ursodeoxycholic
acid (generic name, ursodiol) on elevated serum enzyme activities, bilirubin, cholesterol …

Abstract High‐dose (28‐30 mg/kg/day) ursodeoxycholic acid (UDCA) treatment improves
serum liver tests in patients with primary sclerosing cholangitis (PSC) but does not improve …

Aims: The effect of ursodeoxycholic acid (UDCA) treatment on survival and liver histological
progression of primary sclerosing cholangitis (PSC) remains uncertain. The aim of the …